News
Beam Therapeutics (NASDAQ:BEAM) gains FDA orphan drug status for BEAM-101 to treat sickle cell disease. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback